Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 α enhances the efficacy of chemotherapy in drug-resistant tumor

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3607-3616

  Wang, Yang ^a   Saad, Maha ^a   Pakunlu, Refika I ^a   Khandare, Jayant J ^a   Garbuzenko, Olga B ^a   Vetcher, Alexandre A ^a   Soldatenkov, Viatcheslav A ^b   Pozharov, Vitaly R ^c   Minko, Tamara ^a,d,e  

^a RUTGERS UNIVERSITY   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE PLUS DOXORUBICIN; CASPASE; DOXORUBICIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; MACROGOL; PROTEIN BCL 2; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR NECROSIS; ANIMAL; ATOMIC FORCE MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; DRUG SCREENING; METHODOLOGY; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50349088012     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2020     Document Type: Article

References (28)

1. MinkoT, Kopeckova P, KopecekJ. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release 1999;59:133-48.
2. Fennelly D. Dose intensity in advanced ovarian cancer: have we answered the question ? Clin Cancer Res 1995;1:575-82.
3. Searcey M, Patterson LH. Resistance in cancer: a target for drug discovery. Curr Med Chem Anticancer Agents 2004;4:457 - 60.
4. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8.
5. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
6. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003,29:297 - 307.
7. Wouters BG, Koritzinsky M, Chiu RK.TheysJ, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol 2003:13:31 -41.
8. Wang Y, Pakunlu Rl. TsaoW, Pozharov V, MinkoT. Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor in apoptosis. Mol Pharmacol 2004; 1:156-65.
9. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
10. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an update. Apoptosis 2002:7: 475-82.
11. Kietzmann T, Knabe W, Schmidt-Kastner R. Hypoxia and hypoxia-inducible factor modulated gene expression in brain: involvement in neuroprotection and cell death. Eur Arch Psychiatry Clin Neurosci 2001:251: 170-8.
12. Knowles HJ, Harris AL. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 2001;3:318-22.
13. Pluquet O, Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 2001,174: 1-15.
14. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004;3:608-11.
15. Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 2002:70:599-609.
16. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5.
17. Brune B, von Knethen A, Sandau KB. Transcription factors p53 and HIF-1 α as targets of nitric oxide. Cell Signal 2001;13:525-33.
18. Livingston DM, Shivdasani R. Toward mechanism-based cancer care. JAMA 2001;285:588-93.
19. 19.Wang Y Minko T. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 α antisense oligonucleotides and an anticancer drug. Biochem Pharmacol 2004:68:2031 -42.
20. Pakunlu Rl, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system Cancer Res 2004;64:6214-24.
21. Dharap SS.Wang Y, Chandna P, et al.Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 2005:102 12962-7
22. Dharap SS, Chandna P, Wang Y, et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BH3 peptide enhances the efficacy of chemotherapy J Pharmacol ExpTher 2006:316:992 - 8.
23. Minko T, Kopeckova P. Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 2000:86:108-17.
24. Pakunlu Rl, Wang Y, Saad M, Khandare JJ. Starovoytov V. Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006:114 153-62.
25. Leclere P, Hennebicq E, Calderone A, et al. Supra-molecular organization in block copolymers containing a conjugated segment: a joint AFM/molecular modeling study. Prog Polym Sci 2003:28 55- 81
26. Vetcher A, Gearheart R, Morozov V. Correlation of morphology of electrospun fibers with rheology of linear polyacrylamide solution. Polymer J 2007:39:1 4
27. Betigeri S, Pakunlu Rl,Wang Y, Khandare JJ, Minko T,JNK1 as a molecular target to limit cellular mortality under hypoxia. Mol Pharmacol 2006:3:424 30
28. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv Enzyme Regul 2001;41:189-207